Advertisement

β-Blocker in der Therapie der chronischen Herzinsuffizienz — Wie wirken sie?

  • M. Sigmund

Zusammenfassung

Die Vorstellungen über die Pathophysiologic bei der chronischen Herzinsuffizienz haben sich in den letzten Jahren grundlegend gewandelt. Durch die reduzierte Pumpfunktion des Herzens entspricht das Herzzeitvolumen nicht dem geforderten Bedarf. Im wesentlichen werden zwei Kompensationsmechanismen aktiv, um die zu geringe Herzleistung auszugleichen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, Bartholemew M (1985) A randomized trial of low-dose ß-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 55: 471–475.PubMedCrossRefGoogle Scholar
  2. 2.
    Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F (1991) Exercise hemodynamics and myocardial metabolism during long-term ß-adrenergic blockade in severe heart failure. J Am Coll Cardiol 18: 1059–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Andersson B, Lomsky M, Waagstein F (1993) The link between acute hemodynamic adrenergic ß-blockade and longterm effects in patients with heart failure: A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J 14: 1375–1385.PubMedCrossRefGoogle Scholar
  4. 4.
    Beck FJ, Sigmund M, Richter E, Kallen C, Hanrath P (1993) Verbesserung der anaeroben und aeroben Leistungsfahigkeit bei Patienten mit schwerer Herzinsuffizienz durch eine ß-l-Rezep- torblocker-Therapie. Z Kardiol 82 (Suppl 3): 54.Google Scholar
  5. 5.
    Bennett SK, Fisher ML, Krichten C, Patten RD, Greenberg NL, Gottlieb SS (1993) Ischemic cardiomyopathy treated with metoprolol: Baseline heart rate predicts likelihood of increased ejection fraction. Circulation 88: 1–105.Google Scholar
  6. 6.
    Bristow MR, Ginsburg, R, Monobe W et al. (1972) Decreased catecholamine sensivity and ß- adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205–211.CrossRefGoogle Scholar
  7. 7.
    CIBIS Investigators and Committees (1994) A randomized trial of ß-blockade in heart failure. Circulation 90: 1765–1773.Google Scholar
  8. 8.
    Cohn JN, Levin TB, Olivari MT et al. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 311: 819–823.PubMedCrossRefGoogle Scholar
  9. 9.
    Currie PJ, Kelly MJ, McKenzie A et al. (1984) Oral ß-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 3: 203–209.PubMedCrossRefGoogle Scholar
  10. 10.
    Dies F, Krell MJ, Whitlow P, Liang C, Goldenbeg I, Applefield MM, Gilbert EM (1986) Intermittent dobutamine in ambulatory outpatients with chronic heart failure. Circulation 74: 38.Google Scholar
  11. 11.
    Eichhorn E, Bedotto JB, Malloy CR et al. (1990) Effect of ß-adrenergic blockade on myocardial function and energetics in congestive heart failure: Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 82: 473–383.PubMedCrossRefGoogle Scholar
  12. 12.
    Engelmeier RS, O’Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM (1985) Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 72: 536–546.PubMedCrossRefGoogle Scholar
  13. 13.
    Feldman AM (1993) Modulation of adrenergic receptors aftd G-transduction proteins in failing human ventricular myocardium. Circulation 87: IV 27–34.Google Scholar
  14. 14.
    Feldman MD, Gwathmey JK, Phillips P, Schoen F, Morgan JP (1988) Reversal of the force-fre- quency relationship in working myocardium from patients with endstage heart failure. J Appl Cardiol 3: 273–283.Google Scholar
  15. 15.
    Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP (1994) Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. J Am Coll Cardiol 22: 240–244.Google Scholar
  16. 16.
    Gilbert EM, Anderson JL, Deitchman D et al. (1990) Long-term ß-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind randomized study of bucindolol versus placebo. Am J Med 88: 223–229.PubMedCrossRefGoogle Scholar
  17. 17.
    Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP (1990) Role of intracellular calcium handling in force-interval relationship of human ventricular myocardium. J Clin Invest 85: 1599–1613.PubMedCrossRefGoogle Scholar
  18. 18.
    Imperato-McGinley J, Gautier T, Ehlers K, Zullo T, Goldstein DS Vaughan ED (1987) Rever-sibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocy- toma. N Engl J Med 316: 793–797.PubMedCrossRefGoogle Scholar
  19. 19.
    Ishida S, Makino N, Masutomo K, Hata T, Yanaga T (1993) Effect of metoprolol on the ß-adre- noceptor density of lymphocytes in patients with dilated cardiomyopathy. Am Heart J 125: 1311–1315.PubMedCrossRefGoogle Scholar
  20. 20.
    Komamura K, Shannon RP, Pasipoularides A et al. (1992) Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. J Clin Invest 89: 1825–1838.PubMedCrossRefGoogle Scholar
  21. 21.
    Krum H, Schwartz B, Sackner-Bernstein J et al. (1993) Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe heart failure treated with con-verting-enzyme inhibitors. J Am Coll Cardiol 21 (Suppl A): 114 A.Google Scholar
  22. 22.
    Larosa G, Armstrong PW, Seeman P, Forster C (1993) ß-adrenoceptor recovery after heart fai-lure in the dog. Cardiovasc Res 27: 489–493.PubMedCrossRefGoogle Scholar
  23. 23.
    Leung W, Lau C, Wong C, Cheng C, Tai Y, Lim S (1990) Improvement in exercise performance and hemodynamics by labetalol in patients with dilated cardiomyopathy. Am Heart J 119: 884–890.PubMedCrossRefGoogle Scholar
  24. 24.
    Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR (1992) Altered myocardial force fre-quency relation in human heart failure. Circulation 85: 1743–1750.PubMedGoogle Scholar
  25. 25.
    Olsen SL, Gilbert EM, Renlund DG et al. (1993) Carvedilol improves symptoms and left ven-tricular function in patients with congestive heart failure due to ischemic or idiopathic dilated cardiomyopathy. J Am Coll Cardiol 21 (Suppl A): 114 A.Google Scholar
  26. 26.
    Paolisso G, Gambardella A, Marrazzo G et al. (1992) Metabolic and cardiovascular benefits deriving from ß-adrenergic blockade in chronic congestive heart failure. Am Heart J 123: 103–110.PubMedCrossRefGoogle Scholar
  27. 27.
    Pieske B, Hasenfuss G, Holubarsch C, Schwinger R, Bohm M, Just H (1992) Alterations of the force-frequency relationship in the failing human heart depend on the underlying cardiac disease. Cardiology 87 (pt 1): 213–221.PubMedGoogle Scholar
  28. 28.
    Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML (1990) Usefulness of bucindolol in congestive heart failure. Am J Cardiol 66: 603–607.PubMedCrossRefGoogle Scholar
  29. 29.
    Schwinger RHG, Bohm M, Schmidt U et al. (1995) Unchanged protein levels of SERCA Ü and phospholamban but reduced Ca2+ATPase-activity of cardiac sarcoplasmic reticulum from patients with dilated cardiomyopathy compared to nonfailing patients. Circulation 92: 3320–3228.Google Scholar
  30. 30.
    Sigmund M, Jakob H, Becker H et al. (1996) Effects of metoprolol on myocardial beta-adre- noceptors and Gia-proteins in patients with congestive heart failure. Eur J Pharmacol 51: 127–132.CrossRefGoogle Scholar
  31. 31.
    Szakacs JE, Cannon A (1958) I-Norepinephrine myocarditis. Am J Clin Pathol 30: 425–435.PubMedGoogle Scholar
  32. 32.
    Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of ß -adrenergic receptor kinase and ß1-adrenergic receptors in the failing human heart. Circulation 87: 454–463.PubMedGoogle Scholar
  33. 33.
    Valentine HA, Billingham ME, Heilbrunn SM, Mullin AV, McCrory SP, Schroder JS, Fowler MB (1986) Response to ß-blockers in dilated cardiomyopathy predicted by myocardial biopsy. Circulation 74 (Suppl 4): Ü 309.Google Scholar
  34. 34.
    Van der Berg MP, Veldhuinsen DJ van, Crijns HJGM, Lie KI (1993) Reversion of tachycardio- myopathy after ß-blockers (letter). Lancet 341: 1667.PubMedGoogle Scholar
  35. 35.
    Waagstein F, Blomstom-Ludqvist C, Andersson B, Hjalmarson A, Wallentin I (1987) Long- term effects of metoprolol in severe heart failure due to ischemic cardiomyopathy, primary valve disease and diabetes. Circulation 76 (Suppl 4): IV-358.Google Scholar
  36. 36.
    Waagstein F, Bristow MR, Swedberg K et al. (1993) Beneficial effects of metoprolol in indio- pathic dilated cardiomyopathy. Lancet 342: 1141–1446.CrossRefGoogle Scholar
  37. 37.
    Whyte K, Jones CR, Howie CA, Deighton N, Summer DJ, Reidl JL (1987) Hemodynamic, metabolic and lymphocyte ß-2-adrenoceptor changes following chronic ß-adrenoceptor ant-agonism. Eur J Clin Pharmacol 32: 237–243.PubMedCrossRefGoogle Scholar
  38. 38.
    Woodley SL, Gilbert EM, Anderson JL et al. (1991) Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 2426–2441.PubMedGoogle Scholar
  39. 39.
    Yamada T, Fukunami M, Ohmori M et al. (1993) Which subgroup of patients with dilated car-diomyopathy would benefit from long-term ß-blockers therapy? A histologic viewpoint. J Am Coll Cardiol 21: 628–633.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • M. Sigmund

There are no affiliations available

Personalised recommendations